Compare CRK & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRK | RLAY |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | 1995 | 2020 |
| Metric | CRK | RLAY |
|---|---|---|
| Price | $13.25 | $19.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $22.20 | $19.50 |
| AVG Volume (30 Days) | 2.7M | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 288.16 | 31.78 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $555,231,000.00 | $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.91 | $324.03 |
| P/E Ratio | $32.30 | ★ N/A |
| Revenue Growth | 32.11 | ★ 53.44 |
| 52 Week Low | $12.12 | $4.32 |
| 52 Week High | $28.10 | $21.27 |
| Indicator | CRK | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 50.07 |
| Support Level | $12.56 | $18.03 |
| Resistance Level | $14.25 | $20.82 |
| Average True Range (ATR) | 0.65 | 0.66 |
| MACD | -0.27 | 0.01 |
| Stochastic Oscillator | 12.31 | 66.47 |
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.